摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(4E,6Z,8E)-4-(3-(diethylamino)propoxy)-3-methylazulene-1-carbaldehyde | 1022917-13-0

中文名称
——
中文别名
——
英文名称
(4E,6Z,8E)-4-(3-(diethylamino)propoxy)-3-methylazulene-1-carbaldehyde
英文别名
4-(3-(diethylamino)propoxy)-3-methyl-azulene-1-carbaldehyde;4-(3-(diethylamino)propoxy)-3-methyl-azulen-1-aldehyde;4-[3-(Diethylamino)propoxy]-3-methylazulene-1-carbaldehyde;4-[3-(diethylamino)propoxy]-3-methylazulene-1-carbaldehyde
(4E,6Z,8E)-4-(3-(diethylamino)propoxy)-3-methylazulene-1-carbaldehyde化学式
CAS
1022917-13-0
化学式
C19H25NO2
mdl
——
分子量
299.413
InChiKey
XEMHQNBHGGSBIA-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.8
  • 重原子数:
    22
  • 可旋转键数:
    8
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.42
  • 拓扑面积:
    29.5
  • 氢给体数:
    0
  • 氢受体数:
    3

反应信息

  • 作为反应物:
    参考文献:
    名称:
    Novel azulene-based derivatives as potent multi-receptor tyrosine kinase inhibitors
    摘要:
    A series of azulene-based derivatives were synthesized as potent inhibitors for receptor tyrosine kinases such as FMS-like tyrosine kinase 3 (FLT-3). Systematic side chain modification of prototype 1a was carried out through SAR studies. Analogue 22 was identified from this series and found to be one of the most potent FLT-3 inhibitors, with good pharmaceutical properties, superior efficacy, and tolerability in a tumor xenograft model. (C) 2010 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmcl.2010.08.025
  • 作为产物:
    描述:
    (4-(3-(diethylamino)propoxy)-3-methylazulen-1-yl)methanol 在 manganese(IV) oxide 作用下, 以 二氯甲烷 为溶剂, 生成 (4E,6Z,8E)-4-(3-(diethylamino)propoxy)-3-methylazulene-1-carbaldehyde
    参考文献:
    名称:
    Novel azulene-based derivatives as potent multi-receptor tyrosine kinase inhibitors
    摘要:
    A series of azulene-based derivatives were synthesized as potent inhibitors for receptor tyrosine kinases such as FMS-like tyrosine kinase 3 (FLT-3). Systematic side chain modification of prototype 1a was carried out through SAR studies. Analogue 22 was identified from this series and found to be one of the most potent FLT-3 inhibitors, with good pharmaceutical properties, superior efficacy, and tolerability in a tumor xenograft model. (C) 2010 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmcl.2010.08.025
点击查看最新优质反应信息

文献信息

  • Azulene compounds
    申请人:Lee On
    公开号:US20080125590A1
    公开(公告)日:2008-05-29
    An azulene compound is provided. The azulene compound has formula (I) shown below. Each variable in formula (I) is defined in the specification. One of R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , and R 8 in formula (I) is a moiety of formula (II). The compound can be used to treat cancer.
    提供了一种蓝紫烃化合物。该蓝紫烃化合物的化学式(I)如下所示。化学式(I)中的每个变量在说明书中有定义。化学式(I)中的R1、R2、R3、R4、R5、R6、R7和R8中的一个是化学式(II)的基团。该化合物可用于治疗癌症。
  • US7714146B2
    申请人:——
    公开号:US7714146B2
    公开(公告)日:2010-05-11
  • Novel azulene-based derivatives as potent multi-receptor tyrosine kinase inhibitors
    作者:Chih-Hung Chen、On Lee、Chung-Niang Yao、Meng-Yun Chuang、Yow-Lone Chang、May-Hua Chang、Yen-Fang Wen、Wan-Hsu Yang、Ching-Huai Ko、Nien-Tzu Chou、Mai-Wei Lin、Chin-Pen Lai、Chung-Yuan Sun、Ling-mei Wang、Yen-Chun Chen、Tzong-Hsiung Hseu、Chia-Ni Chang、Hui-Chun Hsu、Hui-Chi Lin、Yu-Li Chang、Ying-Chu Shih、Shuen-Hsiang Chou、Yi-Ling Hsu、Hsiang-Wen Tseng、Chih-Peng Liu、Chia-Mu Tu、Tsan-Lin Hu、Yuan-Jang Tsai、Ting-Shou Chen、Chih-Lung Lin、Shu-Jiau Chiou、Chung-Cheng Liu、Chrong-Shiong Hwang
    DOI:10.1016/j.bmcl.2010.08.025
    日期:2010.10
    A series of azulene-based derivatives were synthesized as potent inhibitors for receptor tyrosine kinases such as FMS-like tyrosine kinase 3 (FLT-3). Systematic side chain modification of prototype 1a was carried out through SAR studies. Analogue 22 was identified from this series and found to be one of the most potent FLT-3 inhibitors, with good pharmaceutical properties, superior efficacy, and tolerability in a tumor xenograft model. (C) 2010 Elsevier Ltd. All rights reserved.
查看更多